Most targeted therapeutics for GBM account for 1 to 2 targets in the GBM tumor, such as epidermal growth factor receptor (EGFR) and isocitrate dehydrogenase (IDH1), allowing cancer cells without expressing specific targets to survive and eventually kill the patient [9, 10]. This evidence concerns the gene IDH3A and glioblastoma.